Christopher Kozlowski

Senior Scientist II at Atsena Therapeutics

Christopher Kozlowski has a diverse work experience. Christopher began their career in 2011 as a Research Technician at Penn State University under the supervision of Dr. Melissa Rolls, where they applied molecular biology and Drosophila model organism approaches to identify proteins regulating microtubule polarity in developing and regenerating neurons. In 2013, they joined Duke University as a Graduate Research Assistant in the Lab of Dr. Jeremy Kay, PhD (Duke Eye Center), where they investigated cellular and molecular mechanisms regulating the formation of retina neural circuits. Christopher then became a Postdoctoral Research Associate in the same lab, where they studied the natural history of mouse models for Leber's Congenital Amaurosis and transgenic mouse design. In 2020, they joined Atsena Therapeutics as a Scientist, and later became a Senior Scientist.

Christopher Kozlowski obtained their Bachelor's of Science in Biochemistry and Molecular Biology from Penn State University in 2013. Christopher then went on to pursue a Doctor of Philosophy in Neurobiology from Duke University, which they completed in 2019.

Location

Raleigh, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. They have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Their additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease.


Industries

Employees

11-50

Links